{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:52:40Z","timestamp":1787169160278,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/idoj.idoj_377_22","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T09:37:54Z","timestamp":1682588274000},"page":"391","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect"],"prefix":"10.4103","volume":"14","author":[{"given":"Aditi","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.375171-1","first-page":"4065437","article-title":"An atypical presentation of lichen planus-like reaction from pembrolizumab","author":"Lee","year":"2019","journal-title":"Case Rep Dermatol Med"},{"key":"key-10.4103\/2229-5178.375171-2","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during Anti-PD-1 therapy","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/2229-5178.375171-3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.375171-4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/2229-5178.375171-5","first-page":"166e72","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.375171-6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.375171-7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.375171-8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"key-10.4103\/2229-5178.375171-9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jdcr.2020.03.007","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma","author":"Kwon","year":"2020","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.375171-10","unstructured":"National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:47:32Z","timestamp":1787165252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_377_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"alternative-id":["375171"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_377_22","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}